Sonoma Bio inks $75M deal with Regeneron to advance cell therapies against autoimmunity

The Seattle-area company, Sonoma Biotherapeutics has partnered with Regeneron in a $75 million upfront deal with plans to co-develop therapies to treat Crohn’s disease and other autoimmune conditions.

The $75 million deal has the potential for $45 million in milestone payments to Sonoma. The companies will combine their technology to identify antibodies to be tested in T cell therapies that fight against Crohn’s, ulcerative colitis, and two undisclosed conditions.

“The Regeneron deal is going to give us a runway to a number of other disease areas,” said Jeff Bluestone, CEO and co-founder of Sonoma Biotherapeutics.